A Study to Gather Information About User Satisfaction in Women in Russia Who Take Estradiol Valerate/Dienogest

Oral Contraception Clinical Trial

— Q-SWAN  

Official title:

A Prospective Multicenter Non-interventional Study to Evaluate User Satisfaction With Estradiol Valerate/ Dienogest in Real Clinical Practice to be Conducted in Russia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04901377
• Other study ID #: 21768
• Status: Completed
• Start date: June 24, 2021
• Est. completion date: April 20, 2023

Study information

• Verified date: September 2023
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Researchers want to learn more about user satisfaction in women in Russia who take estradiol valerate/ dienogest as a contraceptive in real conditions. Estradiol valerate/ dienogest is a form of birth control. This is also known as a combined oral contraceptive (COC). Earlier studies showed that estradiol valerate/ dienogest has high level of protection from unplanned pregnancy. It is available for doctors to prescribe to women who want to take an oral contraceptive. Estradiol valerate/ dienogest as a combined oral contraceptive (COC), works by stopping a process called ovulation. This is the process by which the ovaries release an egg. COCs are commonly used by young women to prevent pregnancy. The researchers in this study will collect information from young women (18-35 years of age) in Russia who will start taking estradiol valerate/ dienogest. The main purpose of this study is to find out about the women's satisfaction with taking estradiol valerate/ dienogest. To do this, the researchers will ask "how satisfied are you with the birth control method used during the study?". They will ask this question after the women have taken estradiol valerate/ dienogest for 3 and 6 months. The women willanswer this question using a rating scale ranging from 1 to 5, with 1 meaning "very dissatisfied" and 5 meaning "very satisfied". This study will include young women (18-35 years of age) who want to use oral contraceptives and have been prescribed estradiol valerate/ dienogest by their doctor. None of the women in the study will have taken estradiol valerate/ dienogest within 1 month of joining the study. In this study, it is expected that each woman will visit her study site 3 times. Each woman will be in the study for up to 6 months. All of the women will take estradiol valerate/ dienogest as prescribed by their doctors. There will be no other required procedures or treatments in this study which is not be used in usual practice. During the study, the women will answer a question about how satisfied they are with estradiol valerate/ dienogest. They will also respond to some questionnaires. These will include a questionnaire about their menstrual bleeding patterns, sexual function. The doctors will: - ask the women about any medical conditions they may have and what other contraceptives they took before they joined the study - check the women's blood pressure and pulse rate - ask a question about woman's intention to continue to use estradiol valerate/ dienogest and the reasons for discontinuation of estradiol valerate/ dienogest if it has happened

Recruitment information / eligibility

• Status: Completed
• Enrollment: 255
• Est. completion date: April 20, 2023
• Est. primary completion date: April 20, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Age from 18 to 35 y.o.
• Indications for administration of estradiol valerate/ dienogest for the purpose of oral contraception.
• Patients who did not take estradiol valerate/ dienogest for at least one month before enrollment into the study.
• Signed informed consent to participate in the study Exclusion criteria
• Participation in an investigational program with interventions outside of routine clinical practice.
• Contraindications to estradiol valerate/ dienogest according to the local market authorization.
• Any medical and non-medical reasons that according to the physician's judgment may prevent patient's participation in the non-interventional study.

Related Conditions & MeSH terms

• Oral Contraception

Intervention

Combination Product:
• Estradiol valerate/ Dienogest
Combined hormonal contraceptive (combined oral contraceptives, COCs)

Locations

Country	Name	City	State
Russian Federation	Many locations	Multiple Locations

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	User satisfaction rates	User satisfaction rates assessed by subjects using an overall satisfaction rating (5-point Likert item) with the following question: "How satisfied are you with the birth control method used during the study?" Answers include: 1 - very dissatisfied; 2 - dissatisfied; 3 - neither satisfied nor dissatisfied; 4 - satisfied; 5 - very satisfied.; Subjects selecting answers #4 or #5 (i.e., subjects expressing satisfaction) will count toward the overall satisfaction rate.	up to 6 months
Secondary	Satisfaction rates assessed by physicians	Satisfaction rates assessed by physicians using an overall satisfaction rating (5-point Likert item) with the following question: "How satisfied are you with the birth control method used during the study?" Answers include: 1 - very dissatisfied; 2 - dissatisfied; 3 - neither satisfied nor dissatisfied; 4 - satisfied; 5 - very satisfied.; Physicians selecting answers #4 or #5 (i.e., physicians expressing satisfaction) will count toward the overall satisfaction rate.	up to 6 months
Secondary	Bleeding profile	The bleeding profile during the previous 3 months and during therapy (visits 2,3), self-reported: regularity (regular, periodically absent, permanently absent); maximum bleeding duration (1-2 days, 3-5 days, 6-7 days, 8 days and more); maximum bleeding intensity (spotting, light bleeding, normal bleeding, heavy bleeding); painful bleeding (yes/ no); inter-menstrual bleeding (yes/ no).	up to 6 months
Secondary	Sexual function using FSFI	Sexual function using "Female Sexual Function Index" (FSFI).	up to 6 months
Secondary	Sexual function using ASQ	Sexual function using Atrophy Symptom Questionnaire (ASQ): dryness; sensitivity; irritation; dyspareunia; vaginal discharge (each symptom will be assessed with the following scale: 0 - normal, 1 - mild, 2 - moderate, 3 - severe).	up to 6 months
Secondary	Reasons for discontinuation		up to 6 months
Secondary	Patient's intentions to continue to take estradiol valerate/ dienogest	yes / no	up to 6 months

External Links

•   Click here for access to information about Bayer's transparency standards and Bayer studies